Hormone therapy prescribing patterns in the United States
Hormone therapy prescribing patterns in the United States
复制标题
DOI：
10.1097/01.aog.0000143826.38439.af
复制
发表时间：
2004-11-01
影响因子：
7.2
通讯作者：
Kessler, L
中科院分区：
文献类型：
--
作者：
Buist, DSM;Newton, KM;Kessler, L
目的：我们试图研究处方模式（患病率以及开始和停止治疗的比率）（激素治疗[HT]和雌激素单药[ET]）在美国妇女健康倡议（WHI）HT试验提前终止的结果发表前2年和发布后5个月。我们对169,586名年龄在40-80岁之间的妇女进行了一项观察性队列研究，这些妇女参加了美国5个健康维护组织，以估计1999年9月1日至6月31日期间HT和ET的患病率以及停药率和启动率。2002年（基线）和2002年12月31日（随访）。我们使用自动化药房数据，以确定所有的口服和经皮雌激素和炔雌醇在studyperiod.Results分发：HT的患病率下降46%，从基线到后续（14.6%至7.9%）; ET使用下降28%，在同一时期（12.6%至9.1%）。HT停药率几乎立即增加，从基线时的2.5%增加到2002年10月的13.8%。我们看到HT和ET启动率立即下降，从0.4%和0.3%，分别在基线，W和ET在follow-up.CONCLUSION：NE扩散的WHI FIT试验结果有立即停止HT和ET的影响，并可能负责的46%和28%的下降，在这些各自的治疗开始。进一步探讨为什么妇女继续使用HT和确定方法，以解决继续使用的原因。(C)2004年由美国妇产科医师学会。
OBJECTIVE: We sought to examine prescribing patterns (prevalence and rates of initiation and discontinuation) for estrogen plus progestin (hormone therapy [HT] and estrogen alone [ET]) in the United States in the 2 years before the published results of Women's Health Initiative's (WHI) HT trial's early termination and for 5 months after their release.METHODS: We conducted an observational cohort study of 169,586 women aged 40-80 years who were enrolled in 5 health maintenance organizations in the United States to estimate the prevalence of HT and ET and discontinuation and initiation rates between September 1, 1999, to June 31, 2002 (baseline), and December 31, 2002 (follow-up). We used automated pharmacy data to identify all oral and transdermal estrogen and progestin dispensed during the study period.RESULTS: The prevalence of HT declined 46% from baseline to follow-up (14.6% to 7.9%); ET use declined 28% during the same period (12.6% to 9.1%). ne discontinuation of HT increased almost immediately, from 2.5% at baseline to 13.8% in October 2002. We saw an immediate decrease in HT and ET initiation rates, from 0.4% and 0.3% at baseline, respectively, to 0.2% for W and ET at follow-up.CONCLUSION: ne diffusion of the WHI FIT trial results had an immediate impact on the discontinuation of HT and ET and is likely responsible for the 46% and 28% decline in the initiation of these respective therapies. Further exploration of why women continue to use HT and identification of methods for addressing reasons for continued use are indicated. (C) 2004 by The American College of Obstetricians and Gynecologists.